Cervical Cancer Gene Database

Lore & Background

The Cervical Cancer gene DataBase (CCDB) was developed as the first manually curated database focusing on genes involved in cervical carcinogenesis. It catalogs 537 genes that have been studied based on polymorphism, methylation, amplification of genes, and changes in how the gene is expressed. The database was designed to present information that may lead to novel therapeutic treatments for cervical cancer, which is a leading cause of cancer among women.

Reader's Guide

The CCDB provides a centralized resource for clinicians and researchers to investigate genes that may lead to the expression of cervical cancer. It includes data on miRNA of the gene, PubMed reports, host and target genes, location and fold change of protein, and expression or alteration of the gene. The database also offers information on tumor-suppressor genes that silence gene expression through hypermethylation. Access is available by searching via gene chromosome number, gene ID, or gene name. Researchers may contribute new data, but it must be validated by the scientific community before inclusion. The database is particularly relevant given that most of the 500,000 women who have succumbed to cervical cancer are from developing countries or low socioeconomic levels in developed countries.

Did You Know?

• The CCDB is the first manually curated database of genes involved in cervical carcinogenesis.
• It catalogs 537 genes based on polymorphism, methylation, amplification, and changes in gene expression.

The Molecular Machinery of HPV-Driven Carcinogenesis

Nearly every case of cervical cancer traces back to a viral infection, making this disease one of the clearest examples of a virus rewriting the rules of human cell biology. Of the more than two hundred known HPV strains, twelve are classified as high-risk, with types 16 and 18 alone responsible for roughly three-quarters of cancers worldwide. The mechanism is elegantly sinister: high-risk HPV subtypes can splice their genetic material directly into the host genome, triggering the production of two viral proteins, E6 and E7. E6 systematically dismantles p53, the cell's primary tumor-suppressing checkpoint, while E7 degrades pRb, another critical brake on uncontrolled cell division. With both guardians gone, cells lose their ability to regulate the cell cycle, and vascular endothelial growth factor surges, feeding new blood vessels to the growing tumor. Most squamous cell carcinomas, about 75 percent of all cervical cancers, are linked to HPV 16, while adenocarcinomas, accounting for another 20 to 25 percent, are more often driven by HPV 18. The transformation from initial infection to invasive cancer typically unfolds over a decade or two, a window that screening programs are designed to intercept.

A Global Burden Disproportionately Felt

Cervical cancer ranks as the fourth most prevalent malignancy among women worldwide and the fourth leading cause of cancer-related death in that population. In 2022, more than 660,000 new diagnoses were recorded globally, accompanied by approximately 350,000 deaths, together representing roughly eight percent of all cancer cases and cancer deaths combined. Yet the distribution of this burden is starkly unequal. Nearly ninety percent of both cases and fatalities are concentrated in low- and middle-income countries, where cervical cancer accounts for seventeen percent of all female cancer diagnoses. In high-income nations, by contrast, it represents only about two percent. This gap is not biological but structural: in developed countries, the widespread implementation of organized cervical screening programs has dramatically curtailed incidence rates. In regions lacking such infrastructure, women often present at advanced stages, when the disease has already metastasized to the abdomen, lungs, or other distant sites, and when symptoms such as severe pelvic pain, leg swelling, or bone fractures have already taken hold. The contrast between these two realities underscores how much of this burden is preventable with the right public-health investment.

From Vaccination to the Operating Theatre

Prevention against cervical cancer operates on two complementary fronts. The first is vaccination: HPV vaccines target between two and seven high-risk viral strains and carry the potential to avert up to ninety percent of cervical cancers. By the close of 2024, 147 countries had incorporated the vaccine into their national immunization schedules for girls, and as of 2022, forty-seven nations extended that protection to boys as well. The second front is screening. Because the vaccines do not cover every oncogenic strain, guidelines continue to recommend regular cervical screening, which can identify precancerous cellular changes before they mature into invasive disease, a transformation that, left unchecked, typically requires ten to twenty years. When cancer does develop, diagnosis usually proceeds through screening followed by a biopsy, with medical imaging then used to map whether the malignancy has spread beyond the cervix. Treatment is tailored to stage and may combine surgery, chemotherapy, radiation therapy, and immunotherapy. In the United States, the five-year survival rate stands at sixty-nine percent, a figure that rises substantially when the cancer is caught early.

HeLa, Awareness, and the Road to Elimination

Few stories in medical history are as intertwined with cervical cancer as that of Henrietta Lacks, whose cervical cancer cells gave rise to HeLa, the most famous immortalized cell line in biomedical research. HeLa cells have become an indispensable tool in laboratories worldwide, underpinning countless studies that continue to advance our understanding of cancer biology. On the public-health front, the fight against cervical cancer gained a powerful institutional anchor on 17 November 2020, when the World Health Organization launched its Global Strategy to accelerate the elimination of cervical cancer as a public health problem. That resolution was endorsed by 194 countries, and the date has since been designated Cervical Cancer Elimination Day of Action. The strategy builds on the recognition that this disease, while devastating, is among the most preventable cancers known: a combination of HPV vaccination, sustained screening programs, and accessible treatment could, in principle, drive incidence to negligible levels. The challenge, as the global statistics make clear, is ensuring that those tools reach the women in low- and middle-income settings who bear the overwhelming share of the disease.